Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N B Modi

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
The Journal of Pharmacology and Experimental Therapeutics|December 23, 1998
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factorY S Lin, C Nguyen, J L Mendoza, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injectionR Yang, S Bunting, A Ko, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarctionN B Modi, N L Fox, F W Clow, et al.
Thrombosis and Haemostasis|February 12, 1998
Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug formC J Refino, N B Modi, S Bullens, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
Journal of Medicinal Chemistry|August 2, 1996
Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidinesT Weller, L Alig, M Beresini, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
The Journal of Pharmacology and Experimental Therapeutics|December 23, 1998
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factorY S Lin, C Nguyen, J L Mendoza, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injectionR Yang, S Bunting, A Ko, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarctionN B Modi, N L Fox, F W Clow, et al.
Thrombosis and Haemostasis|February 12, 1998
Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug formC J Refino, N B Modi, S Bullens, et al.
Circulation|January 21, 1997
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trialC P Cannon, C H McCabe, C M Gibson, et al.
Journal of Medicinal Chemistry|August 2, 1996
Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidinesT Weller, L Alig, M Beresini, et al.
Pageof 4